Use of Immune Suppressive Domains as Medicaments
AssigneesISD Immunotech ApS, Aarhus Universitet
InventorsShervin BAHRAMI, Mogens RYTTERGÅRD DUCH, Christian KANSTRUP HOLM, Magdalena Janina LASKA
Life of this patent
Estimating the term…
Abstract
The present invention concerns uses of immune suppressive domains. In particular, the present invention concerns a use of an immune suppressive domain (ISD) for immune suppression and for reduction of inflammation.
Claims20
Pharmaceutical product comprising an immune suppressive domain from a virus fusion protein as an active substance, wherein said immune suppressive domain is from a virus of the Orthomyxoviridae family.
A pharmaceutical composition comprising an immunosuppressive polypeptide that is a dimer formed by two peptides comprising SEQ ID NO:
- 4 as an active substance subject to at least one of the following provisos:
- (i) said pharmaceutical composition is a parenteral, subcutaneous or oral formulation;
- (ii) said pharmaceutical composition is an injection liquid or infusion liquid;
- (iii) said pharmaceutical composition comprises a pharmaceutically acceptable carrier selected from solid, semisolid and liquid;
- (iv) said pharmaceutical composition is a suspension, solution, emulsion, gel, cream, or powder;
- (v) said pharmaceutical composition comprises 0.5-25% by weight of said peptides in solution;
- or
- (vi) said two peptides comprise SEQ ID NO:
- 4 and an additional cysteine at the C-terminal or N-terminal end of SEQ ID NO:
- 4, wherein said cysteine residues crosslink the two peptides via a disulfide bond.
A peptide comprising SEQ ID NO. 287.
Dependencies are inferred from the claim text.